Hansa Biopharma announces positive Idefirix PAES results presented in the High-Impact Clinical Trials session at ASN Kidney Week
· The 1-year graft failure-free survival at 12 months post-transplant was 90%, which is clinically meaningful · Graft and patient survival were 92% and 98%, respectively · Idefirix was generally well tolerated with a safety profile consistent with previous clinical trial experience Lund, Sweden, October 23, 2026. Hansa…
Extrait seulement — cet éditeur protège son texte. Lisez le communiqué complet à la source.
Forfait Gratuit · Plus 29 $ CA ou Pro 99 $ CA/mois


